Vivesto AB (LON:0N4A)

London flag London · Delayed Price · Currency is GBP · Price in SEK
0.0912
+0.0041 (4.71%)
Feb 12, 2026, 10:29 AM GMT
Market Cap4.51M -50.2%
Revenue (ttm)n/a
Net Income-2.82M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,238
Average Volume9,419
Open0.0912
Previous Close0.0871
Day's Range0.0912 - 0.0912
52-Week Range0.0848 - 0.2360
Beta0.05
RSI26.89
Earnings DateFeb 26, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1988
Employees 4
Stock Exchange London Stock Exchange
Ticker Symbol 0N4A
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements